ID   DOV13
AC   CVCL_6774
SY   DOV-13; DOV 13
DR   BTO; BTO:0003638
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 859
DR   BioSample; SAMN03470841
DR   BioSample; SAMN10988354
DR   cancercelllines; CVCL_6774
DR   Cell_Model_Passport; SIDM00969
DR   ChEMBL-Cells; CHEMBL3307753
DR   ChEMBL-Targets; CHEMBL615004
DR   Cosmic; 924143
DR   Cosmic; 927565
DR   Cosmic-CLP; 1479987
DR   DepMap; ACH-001063
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 1479987
DR   GEO; GSM659373
DR   GEO; GSM711724
DR   GEO; GSM851916
DR   GEO; GSM1340578
DR   GEO; GSM1341128
DR   GEO; GSM1669743
DR   IARC_TP53; 28278
DR   Millipore; SCC186
DR   PharmacoDB; DOV13_307_2019
DR   PRIDE; PXD003668
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_6774
DR   PubChem_Cell_line; CVCL_6774
DR   Wikidata; Q54831365
RX   PubMed=1536252;
RX   PubMed=7836420;
RX   PubMed=10318951;
RX   PubMed=10972993;
RX   PubMed=16380993;
RX   PubMed=22710073;
RX   PubMed=23415752;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=27561551;
RX   PubMed=30485824;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: African American.
CC   Doubling time: 36.05 hours (GrayJW panel).
CC   HLA typing: A*30:02,74:01; B*15:03,51:01; C*02:02,16:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Microsatellite instability: Instable (MSI) (PubMed=31068700).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Ser (c.840A>T); ClinVar=VCV000988616; Zygosity=Heterozygous (DepMap).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Genome sequenced.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=86.88%; Native American=0.11%; East Asian, North=5.26%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=7.75% (PubMed=30894373).
CC   Misspelling: DOR 13; ArrayExpress=E-MTAB-2706; PubMed=25485619; PubMed=25877200.
CC   Misspelling: DOR13; PubMed=26589293.
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
ST   Source(s): Cosmic-CLP; Genomics_Center_BCF_Technion; Millipore; PubMed=22710073; PubMed=25877200; PubMed=30485824
ST   Amelogenin: X
ST   CSF1PO: 8,10
ST   D10S1248: 13
ST   D12S391: 16,20
ST   D13S317: 11
ST   D16S539: 10,13
ST   D18S51: 12,16
ST   D19S433: 13,14
ST   D1S1656: 15,16.3
ST   D21S11: 32.2,33.2
ST   D22S1045: 17
ST   D2S1338: 20,24
ST   D2S441: 14
ST   D3S1358: 14,16
ST   D5S818: 11
ST   D7S820: 10 (Cosmic-CLP; Genomics_Center_BCF_Technion; Millipore; PubMed=22710073; PubMed=25877200)
ST   D7S820: 10,11 (PubMed=30485824)
ST   D8S1179: 12,14 (Millipore)
ST   D8S1179: 14 (Genomics_Center_BCF_Technion; PubMed=22710073; PubMed=25877200)
ST   FGA: 21,24
ST   Penta D: 3.2,8
ST   Penta E: 8
ST   TH01: 6,9.3
ST   TPOX: 6,8
ST   vWA: 17,19 (Millipore)
ST   vWA: 19 (Cosmic-CLP; Genomics_Center_BCF_Technion; PubMed=22710073; PubMed=25877200; PubMed=30485824)
DI   NCIt; C7700; Ovarian adenocarcinoma
DI   ORDO; Orphanet_213504; Adenocarcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 37
//
RX   PubMed=1536252; DOI=10.1016/0002-9378(92)91697-9;
RA   Berchuck A., Rodriguez G., Olt G., Whitaker R., Boente M.P.,
RA   Arrick B.A., Clarke-Pearson D.L., Bast R.C. Jr.;
RT   "Regulation of growth of normal ovarian epithelial cells and ovarian
RT   cancer cell lines by transforming growth factor-beta.";
RL   Am. J. Obstet. Gynecol. 166:676-684(1992).
//
RX   PubMed=7836420; DOI=10.1074/jbc.270.3.999;
RA   Young T.N., Pizzo S.V., Stack M.S.;
RT   "A plasma membrane-associated component of ovarian adenocarcinoma
RT   cells enhances the catalytic efficiency of matrix metalloproteinase-2.";
RL   J. Biol. Chem. 270:999-1002(1995).
//
RX   PubMed=10318951; DOI=10.1073/pnas.96.10.5722;
RA   Lau K.-M., Mok S.C., Ho S.-M.;
RT   "Expression of human estrogen receptor-alpha and -beta, progesterone
RT   receptor, and androgen receptor mRNA in normal and malignant ovarian
RT   epithelial cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:5722-5727(1999).
//
RX   PubMed=10972993; DOI=10.1002/1098-2744(200008)28:4<236::AID-MC6>3.0.CO;2-H;
RA   Rauh-Adelmann C., Lau K.-M., Sabeti N., Long J.P., Mok S.C., Ho S.-M.;
RT   "Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon
RT   12 deletion variant in malignant human ovarian, prostate, and breast
RT   cancer cell lines.";
RL   Mol. Carcinog. 28:236-246(2000).
//
RX   PubMed=16380993; DOI=10.1002/ijc.21671;
RA   Huang K.-C., Park D.C., Ng S.-K., Lee J.Y., Ni X.-Y., Ng W.-C.,
RA   Bandera C.A., Welch W.R., Berkowitz R.S., Mok S.C., Ng S.-W.;
RT   "Selenium binding protein 1 in ovarian cancer.";
RL   Int. J. Cancer 118:2433-2440(2006).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007;
RA   Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S.,
RA   Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G.,
RA   Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J.,
RA   Mills G.B., Hennessy B.T.;
RT   "BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one
RT   functionally deleterious BRCA1 mutation.";
RL   Mol. Oncol. 7:567-579(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27561551; DOI=10.1038/ncomms12645;
RA   Coscia F., Watters K.M., Curtis M., Eckert M.A., Chiang C.Y.,
RA   Tyanova S., Montag A., Lastra R.R., Lengyel E., Mann M.;
RT   "Integrative proteomic profiling of ovarian cancer cell lines reveals
RT   precursor cell associated proteins and functional status.";
RL   Nat. Commun. 7:12645.1-12645.14(2016).
//
RX   PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096;
RA   Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M.,
RA   Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R.,
RA   Press M.F., Drapkin R.I., Easwaran H., Baylin S.B., Slamon D.J.,
RA   Velculescu V.E., Scharpf R.B.;
RT   "Integrated genomic, epigenomic, and expression analyses of ovarian
RT   cancer cell lines.";
RL   Cell Rep. 25:2617-2633(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//